Form 4: Beam Therapeutics Director Acquires 39,086 Stock Options

A Beam Therapeutics director, Chirfi Guindo, acquired 39,086 stock options on December 2, 2024, at an exercise price of $28.30.

Summary

• Chirfi Guindo, a director at Beam Therapeutics, acquired 39,086 stock options on December 2, 2024.
• The exercise price for these options is $28.30 per share.
• The options vest over a three-year period, with one-third vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments over the following two years.
• The options expire on December 2, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, which is neither positive nor negative in itself.

Industry Context

This is a standard Form 4 filing, which is common for directors and officers of publicly traded companies when they acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in the biotechnology industry.
• The vesting schedule of one-third after one year and the remainder over two years is a typical vesting structure.
• The 10-year expiration date is also standard for stock options.

Stakeholder Impact

• The stock option grant may have a minor positive impact on employee morale as it aligns director interests with shareholder value.

Key Dates

Keywords

stock options, insider trading, director, equity, Beam Therapeutics, BEAM